Fenofibrate, a peroxisome proliferator-activated receptor a agonist, improves hepatic microcirculatory patency and oxygen availability in a high-fat-diet-induced fatty liver in mice

Kazunari Kondo, Tadao Sugioka, Kosuke Tsukada, Michiyoshi Aizawa, Masayuki Takizawa, Kenji Shimizu, Masaya Morimoto, Makoto Suematsu, Nobuhito Goda

    Research output: Chapter in Book/Report/Conference proceedingConference contribution

    23 Citations (Scopus)

    Abstract

    Nonalcoholic fatty liver disease (NAFLD) is a common disease of chronic liver diseases. Peroxisome proliferator-activated receptor a (PPARa) has been implicated to play important roles in the development of the disease. Beyond its effects on lipidmetabolisms, PPARa activation in the vascular system has emerged as an attractive therapeutic potential for NAFLD, although its actions in the microcirculatory system are not fully understood. In this study, we investigated the effects of fenofibrate, a PPARa synthetic agonist, on hepatic microcirculation in a high-fat diet (HFD)-induced fatty liver in mice. In vivo imaging analysis revealed the adverse effects of HFDon hepatic vasculature with narrowing of hepatic sinusoids and hepatic microcirculatory perfusion. Oxygen tension was significantly decreased in portal venules, while NADH autofluorescence in hepatocytes was greatly elevated. Fenofibrate treatment remarkably improved microvascular patency, tissue oxygenation and redox states in the affected liver. These results suggest beneficial roles of PPARa activated by fenofibrate on the regulation of both lipid metabolisms and microvascular environments of oxygen metabolism in HFD-induced fatty liver.

    Original languageEnglish
    Title of host publicationAdvances in Experimental Medicine and Biology
    Pages77-82
    Number of pages6
    Volume662
    DOIs
    Publication statusPublished - 2010

    Publication series

    NameAdvances in Experimental Medicine and Biology
    Volume662
    ISSN (Print)00652598

    Fingerprint

    Fenofibrate
    Peroxisome Proliferator-Activated Receptors
    High Fat Diet
    Fatty Liver
    Nutrition
    Liver
    Fats
    Availability
    Oxygen
    Venules
    Microcirculation
    Oxygenation
    Lipid Metabolism
    NAD
    Oxidation-Reduction
    Blood Vessels
    Liver Diseases
    Hepatocytes
    Metabolism
    Chronic Disease

    ASJC Scopus subject areas

    • Biochemistry, Genetics and Molecular Biology(all)
    • Medicine(all)

    Cite this

    Kondo, K., Sugioka, T., Tsukada, K., Aizawa, M., Takizawa, M., Shimizu, K., ... Goda, N. (2010). Fenofibrate, a peroxisome proliferator-activated receptor a agonist, improves hepatic microcirculatory patency and oxygen availability in a high-fat-diet-induced fatty liver in mice. In Advances in Experimental Medicine and Biology (Vol. 662, pp. 77-82). (Advances in Experimental Medicine and Biology; Vol. 662). https://doi.org/10.1007/978-1-4419-1241-1_10

    Fenofibrate, a peroxisome proliferator-activated receptor a agonist, improves hepatic microcirculatory patency and oxygen availability in a high-fat-diet-induced fatty liver in mice. / Kondo, Kazunari; Sugioka, Tadao; Tsukada, Kosuke; Aizawa, Michiyoshi; Takizawa, Masayuki; Shimizu, Kenji; Morimoto, Masaya; Suematsu, Makoto; Goda, Nobuhito.

    Advances in Experimental Medicine and Biology. Vol. 662 2010. p. 77-82 (Advances in Experimental Medicine and Biology; Vol. 662).

    Research output: Chapter in Book/Report/Conference proceedingConference contribution

    Kondo, K, Sugioka, T, Tsukada, K, Aizawa, M, Takizawa, M, Shimizu, K, Morimoto, M, Suematsu, M & Goda, N 2010, Fenofibrate, a peroxisome proliferator-activated receptor a agonist, improves hepatic microcirculatory patency and oxygen availability in a high-fat-diet-induced fatty liver in mice. in Advances in Experimental Medicine and Biology. vol. 662, Advances in Experimental Medicine and Biology, vol. 662, pp. 77-82. https://doi.org/10.1007/978-1-4419-1241-1_10
    Kondo K, Sugioka T, Tsukada K, Aizawa M, Takizawa M, Shimizu K et al. Fenofibrate, a peroxisome proliferator-activated receptor a agonist, improves hepatic microcirculatory patency and oxygen availability in a high-fat-diet-induced fatty liver in mice. In Advances in Experimental Medicine and Biology. Vol. 662. 2010. p. 77-82. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/978-1-4419-1241-1_10
    Kondo, Kazunari ; Sugioka, Tadao ; Tsukada, Kosuke ; Aizawa, Michiyoshi ; Takizawa, Masayuki ; Shimizu, Kenji ; Morimoto, Masaya ; Suematsu, Makoto ; Goda, Nobuhito. / Fenofibrate, a peroxisome proliferator-activated receptor a agonist, improves hepatic microcirculatory patency and oxygen availability in a high-fat-diet-induced fatty liver in mice. Advances in Experimental Medicine and Biology. Vol. 662 2010. pp. 77-82 (Advances in Experimental Medicine and Biology).
    @inproceedings{ff9cddafb85c49ef868c8341647e2251,
    title = "Fenofibrate, a peroxisome proliferator-activated receptor a agonist, improves hepatic microcirculatory patency and oxygen availability in a high-fat-diet-induced fatty liver in mice",
    abstract = "Nonalcoholic fatty liver disease (NAFLD) is a common disease of chronic liver diseases. Peroxisome proliferator-activated receptor a (PPARa) has been implicated to play important roles in the development of the disease. Beyond its effects on lipidmetabolisms, PPARa activation in the vascular system has emerged as an attractive therapeutic potential for NAFLD, although its actions in the microcirculatory system are not fully understood. In this study, we investigated the effects of fenofibrate, a PPARa synthetic agonist, on hepatic microcirculation in a high-fat diet (HFD)-induced fatty liver in mice. In vivo imaging analysis revealed the adverse effects of HFDon hepatic vasculature with narrowing of hepatic sinusoids and hepatic microcirculatory perfusion. Oxygen tension was significantly decreased in portal venules, while NADH autofluorescence in hepatocytes was greatly elevated. Fenofibrate treatment remarkably improved microvascular patency, tissue oxygenation and redox states in the affected liver. These results suggest beneficial roles of PPARa activated by fenofibrate on the regulation of both lipid metabolisms and microvascular environments of oxygen metabolism in HFD-induced fatty liver.",
    author = "Kazunari Kondo and Tadao Sugioka and Kosuke Tsukada and Michiyoshi Aizawa and Masayuki Takizawa and Kenji Shimizu and Masaya Morimoto and Makoto Suematsu and Nobuhito Goda",
    year = "2010",
    doi = "10.1007/978-1-4419-1241-1_10",
    language = "English",
    isbn = "9781441912398",
    volume = "662",
    series = "Advances in Experimental Medicine and Biology",
    pages = "77--82",
    booktitle = "Advances in Experimental Medicine and Biology",

    }

    TY - GEN

    T1 - Fenofibrate, a peroxisome proliferator-activated receptor a agonist, improves hepatic microcirculatory patency and oxygen availability in a high-fat-diet-induced fatty liver in mice

    AU - Kondo, Kazunari

    AU - Sugioka, Tadao

    AU - Tsukada, Kosuke

    AU - Aizawa, Michiyoshi

    AU - Takizawa, Masayuki

    AU - Shimizu, Kenji

    AU - Morimoto, Masaya

    AU - Suematsu, Makoto

    AU - Goda, Nobuhito

    PY - 2010

    Y1 - 2010

    N2 - Nonalcoholic fatty liver disease (NAFLD) is a common disease of chronic liver diseases. Peroxisome proliferator-activated receptor a (PPARa) has been implicated to play important roles in the development of the disease. Beyond its effects on lipidmetabolisms, PPARa activation in the vascular system has emerged as an attractive therapeutic potential for NAFLD, although its actions in the microcirculatory system are not fully understood. In this study, we investigated the effects of fenofibrate, a PPARa synthetic agonist, on hepatic microcirculation in a high-fat diet (HFD)-induced fatty liver in mice. In vivo imaging analysis revealed the adverse effects of HFDon hepatic vasculature with narrowing of hepatic sinusoids and hepatic microcirculatory perfusion. Oxygen tension was significantly decreased in portal venules, while NADH autofluorescence in hepatocytes was greatly elevated. Fenofibrate treatment remarkably improved microvascular patency, tissue oxygenation and redox states in the affected liver. These results suggest beneficial roles of PPARa activated by fenofibrate on the regulation of both lipid metabolisms and microvascular environments of oxygen metabolism in HFD-induced fatty liver.

    AB - Nonalcoholic fatty liver disease (NAFLD) is a common disease of chronic liver diseases. Peroxisome proliferator-activated receptor a (PPARa) has been implicated to play important roles in the development of the disease. Beyond its effects on lipidmetabolisms, PPARa activation in the vascular system has emerged as an attractive therapeutic potential for NAFLD, although its actions in the microcirculatory system are not fully understood. In this study, we investigated the effects of fenofibrate, a PPARa synthetic agonist, on hepatic microcirculation in a high-fat diet (HFD)-induced fatty liver in mice. In vivo imaging analysis revealed the adverse effects of HFDon hepatic vasculature with narrowing of hepatic sinusoids and hepatic microcirculatory perfusion. Oxygen tension was significantly decreased in portal venules, while NADH autofluorescence in hepatocytes was greatly elevated. Fenofibrate treatment remarkably improved microvascular patency, tissue oxygenation and redox states in the affected liver. These results suggest beneficial roles of PPARa activated by fenofibrate on the regulation of both lipid metabolisms and microvascular environments of oxygen metabolism in HFD-induced fatty liver.

    UR - http://www.scopus.com/inward/record.url?scp=77949889327&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=77949889327&partnerID=8YFLogxK

    U2 - 10.1007/978-1-4419-1241-1_10

    DO - 10.1007/978-1-4419-1241-1_10

    M3 - Conference contribution

    C2 - 20204774

    AN - SCOPUS:77949889327

    SN - 9781441912398

    VL - 662

    T3 - Advances in Experimental Medicine and Biology

    SP - 77

    EP - 82

    BT - Advances in Experimental Medicine and Biology

    ER -